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ABSTRACT 
The fundamental role of the brain-specific myelin transcription factor 1-like 
(MYT1L) gene in cases of intellectual disability and in the aetiology of 
neurodevelopmental disorders is increasingly recognised. Yet, its function remains 
under-investigated. Here, we identify a network of helix-loop-helix (HLH) 
transcriptional regulators controlled by MYT1L, as indicated by our analyses in 
human neural stem cells and in the human brain. Using cell-based knockdown 
approaches and microarray analyses we found that (i) MYT1L is required for 
neuronal differentiation and identified ID1, a HLH inhibitor of premature 
neurogenesis, as a target. (2) While MYT1L prevented expression of ID1, it induced 
expression of a large number of terminal differentiation genes. (3) Consistently, 
expression of MYT1L in the human brain coincided with neuronal maturation and 
inversely correlated with that of ID1 and ID3 throughout the lifespan. (4) Genetic 
polymorphisms that reduced expression of MYT1L in the hippocampus resulted in 
increased expression of ID1 and ID3, decreased levels of the proneural basic HLH 
(bHLH) transcriptional regulators TCF4 and NEUROD6 and decreased expression of 
genes involved in long-term potentiation and synaptic transmission, cancer and 
neurodegeneration. Furthermore, our neuroimaging analyses indicated that MYT1L 
expression associated with hippocampal volume and activation during episodic 
memory recall, as measured by blood-oxygen-level dependent (BOLD) signals. 
Overall, our findings suggest that MYT1L influences memory-related processes by 
controlling a neuronal proliferation/differentiation switch of ID-bHLH factors. 
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INTRODUCTION 
The generation of post-mitotic neurons from proliferating progenitors, their 
differentiation and migration to their final positions in the brain, the axonal 
outgrowth and the generation of functional synapses are key events required for 
normal brain development throughout life. Any disturbance in these coordinated 
steps can result in intellectual inability and serious developmental and 
neurodegenerative disorders (Vaillend et al, 2008).  
 
The coordinated actions of transcriptions factors that drive tissue- and 
developmental stage-specific programmes of gene expression tightly regulate cell 
fate specification and differentiation. Progression through neurogenesis is partly 
determined by the sequential activities of evolutionarily conserved basic helix-loop-
helix (bHLH) transcription factors. Generally, the determination genes ATOH1, 
NEUROD4, ASCL1, NEUROG1 and NEUROG2 initiate neurogenesis and induce the 
expression of the differentiation effectors NEUROD1, NEUROD2 and NEUROD6 
(Sugimori et al, 2007). Given the complexity of cell fate determination processes, it is 
not surprising that the activity of proneural bHLH needs to be tightly regulated. To 
become transcriptionally active, these powerful tissue-specific transcription factors 
must form heterodimers with more broadly expressed bHLH proteins, or E-proteins, 
encoded by the TCF4, TCF3, and TCF12 genes in humans. Conversely, their function is 
counteracted by another class of HLH proteins, the inhibitor of differentiation (ID). 
These dominant negative ID proteins control cell fate determination and inhibit 
differentiation during development and in adult life by sequestering bHLH proteins 
(For a recent review, see (Wang and Baker, 2015)). ID genes have various patterns of 
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expression, with high Id1 expression a characteristic of neural stem cells. Deletion of 
both Id1 and Id3 in mice results in severe phenotypes, including embryonic lethality 
with cardiac defects, premature withdrawal of neuroblasts from the cell cycle and 
premature neuronal differentiation (Lyden et al, 1999). These phenotypes of 
Id1−/−/Id3−/− mice, not seen in the single mutants, illustrate substantial functional 
overlap between these two genes. 
 
Another transcription factor that may regulate tissue- and developmental stage-
specific programmes of gene expression is myelin transcription factor 1-like (MYT1L), 
a brain-specific transcription factor that may be required for the expression of 
neuronal genes. This is suggested by the findings that the encoded protein is 
sufficient to convert mouse embryonic fibroblasts into functional neurons when 
overexpressed together with two other transcription factors, Brn2 and Ascl1 cells 
(Vierbuchen et al, 2010). While in this report Myt1l did not seem to be necessary for 
reprogramming process per se, it enhanced the differentiated phenotypes of 
neurons, suggesting a role for this gene in neuronal maturation. The formation of 
such induced neuronal cells appears to be more complicated in humans. While 
overexpression of MYT1L together with BRN2 and ASCL1 could generate functional 
neurons from human pluripotent stem cells, further addition of NEUROD1 is 
necessary to convert human fibroblasts into neuronal cells (Pang et al, 2011). This 
highlights cell-type and species-specific effects of MYT1L and other lineage-
determining transcription factors. A role for MYT1L in neural development is further 
supported by the identification of MYT1L mutations in patients diagnosed with 
various neurodevelopmental disorders. The identification of mutations on 
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chromosome band 2p25.3 disrupting the MYT1L gene in patients with mild to 
moderate intellectual disability and speech delay (Bonaglia et al, 2014; de Ligt et al, 
2012; De Rocker et al, 2015; Mayo et al, 2015; Stevens et al, 2011) provided the first 
links between haploinsufficiency of MYT1L and intellectual disability (De Rocker et al, 
2015). MYT1L mutations have also been associated with diseases, such as 
schizophrenia (Lee et al, 2012; Vrijenhoek et al, 2008), autism (De Rubeis et al, 2014; 
Meyer et al, 2012) and major depressive disorder (Wang et al, 2010). 
 
Despite such links with disease, there has been little research to date on the 
mechanisms by which MYT1L contributes to neuronal differentiation and its 
associations with relevant human brain phenotypes. To address this, we investigated 
the consequences MYT1L depletion on gene expression and neural differentiation in 
human neural stem cells in culture and in the human brain. We also measured 
associations between MYT1L genotypes with hippocampal structure and function 
using structural and functional neuroimaging. These analyses highlight a previously 
unrecognized MYT1L-dependant transcriptional network that offers a unique 
opportunity to understand the pleiotropic roles of MYT1L in human disease. 
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 MATERIALS AND METHODS 
 
Knocking-down MYT1L in cultured cells 
To inhibit MYT1L function in human neural stem cells, we transduced the SPC04 cell 
line (Desrivières et al, 2015) with lentiviruses encoding either a control short hairpin 
RNA (shRNA) or a shRNA against MYT1L and measured the consequences on gene 
expression as indicated below.  
Lentiviral production and transduction of neural stem cell cultures: eGFP-containing 
pGIPZ lentiviral vector with the shRNAmir sequence targeting MYT1L 
(V2LMM_32678) or the non-silencing shRNAmir (RHS4346) were obtained from the 
Open Biosystem shRNAmir library (Thermofisher Scientific Open Biosystems, UK).  
The sense target sequences for these shRNAs were: MYT1L: 5’–
CCGTGACTACTTTGACGGAAAT–3’; non-silencing control: 5’–
ATCTCGCTTGGGCGAGAGTAAG–3’. Replication incompetent lentiviruses containing 
the MYT1L or non-silencing shRNAmir were obtained by transfecting HEK 293T cells 
using the Trans-lentiviral GIPZ Packaging System (Thermofisher Scientific Open 
Biosystems, UK) following the manufacturer’s instructions. Supernatants containing 
lentiviruses were collected 48h and 72h post transfection, pooled, cleared by 
centrifugation at 1600 x g at 4°C for 10 minutes, filtered and ultracentrifuged at 
25,000 rpm for 1.5 hours at 4°C. Supernatants were carefully removed and lentiviral 
pellets resuspended in 30 µl of Phosphate Buffered Saline and aliquoted for storage 
at -80°C until use. One day before transduction, SPC-04 cells were seeded in 6-well 
laminin-coated plates at 20,000 cells/cm2. The following day, the growth media was 
replaced by the pre-differentiation medium in the presence of 3.5x105 TU/ml of 
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lentivirus and the cells were incubated for 48h, after which differentiation was 
induced. Transduction efficiency was monitored by a fluorescent microscope (Leica 
DMIL) with a Leica camera DFC420C (x10 objective). 
 
Gene expression analyses: Effects of shRNAs on MYT1L mRNA levels and on global 
gene expression were assessed by quantitative PCR (qPCR) and microarray analyses. 
qPCR analyses: cDNAs obtained by reverse-transcription using the SuperScript® III 
First-Strand Synthesis System (Invitrogen) following the manufacturer’s instructions, 
were amplified by PCR. RNA expression levels were assessed with RPL18 (60S 
Ribosomal Protein L18) as internal controls for normalisation, using the following 
forward and reverse primers: RPL18 forward  5’–GAGAGGTGTACCGGCATTTC–
3’, reverse 5’–CTCTGGCACGCTCGAACT–3’; MYT1L forward 5’–
TGGAGAGCAACCTGAAGACC–3’, reverse 5’–ATTCCTCTCACAGCCTGCTT–3’. PCRs 
were run in triplicate in the Applied Biosystems real-time PCR device (7900HT Fast 
Real Time PCR system) in 20μl reactions containing 4μl cDNA, 0.5μM of each forward 
and reverse primers and 1x Power SYBR Green Mix (Applied Biosystems) using the 
following cycles: 95°C for 15 minutes and 40 cycles at 95°C for 30 seconds and 59°C 
for 30 seconds. The PCR reaction products were evaluated by a melting curve 
analysis and the PCR products quantified using the SDS software (Applied 
Biosystems) comparing threshold cycles (Ct). Statistical analysis was performed on 
the delta Ct values (i.e., experimental Ct - control Ct) by ANOVA, followed by 
Bonferroni- or Dunnett- based post-hoc analyses (α = 0.05, 2-sided) using the SPSS® 
software. 
Microarray analyses: Total RNA samples were processed using the TargetAmp™-
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Nano Labeling Kit (Cambio Ltd.) and hybridized to Illumina HumanHT-12 v4 
Expression BeadChips according to the manufacturers’ instructions at the High-
Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics, 
Oxford. Raw data extracted by the Illumina BeadStudio software were further 
processed in R statistical environment (http://www.r-project.org). Raw expression 
data were pre-processed by variance stabilizing transformation and quantile 
normalization using the lumi package. Non-detected probes and probes that did not 
vary, based on median coefficient of variation across arrays, were filtered out. 
Differential expression between control versus knockdown conditions was assessed 
using the limma package.  P values were adjusted for multiple testing according to 
the false discovery rate (FDR) procedure of Benjamini and Hochberg and 
differentially expressed genes were selected at FDR < 5%. The functional annotation 
clustering tool, part of the Database for Annotation, Visualisation and Integrated 
Discovery (DAVID) web server (Huang et al, 2009) was used to determine enrichment 
of functional groups in set of genes mapped by differentially expressed probes (at 
FDR ≤ 10%). Clustered GO terms with PEASE ≤ 0.01 (i.e., enrichment scores > 2) were 
considered specifically enriched.  
 
Gene expression analyses in post-mortem human brain samples 
We analysed publicly available datasets to follow spatiotemporal gene expression 
patterns in the human brain and identify expression quantitative trait loci (eQTL) in 
MYT1L (i.e., single nucleotide polymorphisms (SNPs) associated with differences in 
gene expression). These are detailed in the Supplementary Methods. 
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Magnetic Resonance Imaging (MRI) study of the human hippocampus 
To investigate the impact of MYT1L SNPs on hippocampus structure and function in 
the living human brain, we used structural MRI and an established reliable functional 
MRI (fMRI) neuroimaging task (Erk et al, 2010). 
 
Human structural MRI analyses: 
Subjects: a sample of N = 1583 adolescents (age = 14.57 ± 0.45), participants of the 
IMAGEN project (Schumann et al, 2010) were analysed in this study.  Written 
informed consent was obtained from all participants and their legal guardians.  
Magnetic Resonance Imaging. Details of the MRI protocols and quality checks are in 
the Supplementary Methods. Out of 1,909 images, 1,583 passed these quality 
control checks and were used in association analyses with MYT1L genotypes.  
SNP genotyping and quality controls and selection of MYT1L genotypes. DNA 
purification and genotyping procedures have been described previously (Desrivières 
et al, 2015). Ninety five SNPs contained within the MYT1L locus and its surrounding ± 
10 kb region were selected and the corresponding genotypes extracted from 
genome-wide information collected at 502,160 SNPs for 1,837 subjects (900 males, 
937 females) using PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/). This 
dataset had been filtered to remove SNPs with call rates of <98%, minor allele 
frequency <1% or deviation from the Hardy-Weinberg equilibrium (P ≤ 1×10-4), and 
individuals with >2% missing genotypes or of unspecified sex.  
Genetic association analyses. Linkage disequilibrium (LD)-based set test association 
analyses were performed, testing for the additive dosage of each SNP on the 
volumes of the right and left hippocampus using the --set-test function of PLINK, 
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with the following parameters: LD threshold = 0.5, SNP p-value threshold = 0.01; 
Maximum number of independent SNPs = 5. Empirical p-value for the MYT1L set was 
obtained after 10,000 permutations. Gender, intracranial volume and dummy 
variables for scanning site were used as covariates of no interest in the analyses. 
Handedness and age did not influence the above associations and were not included 
as a covariate in our analyses. For the single SNP associations of rs17338519 with 
hippocampal volume, linear regression analyses were performed using the same 
covariates as above. Results presented for these analyses included from 1,398 
individuals with non-missing status (900 males, 937 females; 1,227 right handed). 
 
Human fMRI study of episodic memory recall 
Subjects. 285 healthy adults (mean age 34.0 +/- 9.8) German volunteers with 
grandparents of European ancestry were recruited at Bonn, Mannheim and Berlin. 
Participants had no history of any neurological disorder or current psychiatric Axis I 
disorder including drug or alcohol dependence, as verified by SCID-I. The study was 
approved by the local ethics committees of the Universities of Bonn, Heidelberg and 
Berlin and all subjects gave written informed consent to the study. N=3 subjects 
were rs17338519 AA homozygotes, n=42 AC heterozygotes and n=240 CC 
homozygotes. The allele frequencies were in Hardy-Weinberg equilibrium. Genotype 
distributions did not differ between sites. Gender, age, handedness and level of 
education, did not differ significantly between genotype groups.  
DNA-extraction and genotyping. Genotype data for rs17338519 were extracted from 
a genome-wide data set generated at the Department of Genomics, Life & Brain 
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Center, University of Bonn using Human610-Quad Bead Arrays (Illumina, San Diego, 
CA, USA).  
Functional imaging task. During functional MRI scanning, subjects completed an 
episodic memory task that was part of three consecutive memory tasks, i.e. 
encoding, recall and recognition of face-profession pairs (for a detailed description 
see (Erk et al, 2010)). During recall, the task in focus here, faces were presented 
together with the question whether the depicted person had to complete 
apprenticeship or academic studies in order to qualify for the respective profession 
that had been learned during encoding. Subjects had to indicate by button press, 
which qualification was correct. In the control condition, subjects had to assess 
whether the left or the right ear of different head contours was larger. The task 
consisted of 4 blocks of 4 faces (a 6s) and 4 blocks of 6 head contours (a 4s) each. 
Each block lasted 24s. Task parameters and image processing are detailed in the 
Supplementary Methods. 
For each subject, statistical contrast images of memory versus control were obtained 
and analysed using the general linear model in a second-level random effects 
analysis (two-sample t-test) with site, age, gender and hippocampal volume as 
covariates. Given the small number of AA individuals, we pooled individuals with 
either one or two copies of the A allele (AA,AC). We used a region of interest (ROI) 
approach to investigate BOLD signals in the hippocampus, using anatomical labels 
provided by the Wake Forest University PickAtlas 
(www.fmri.wfubmc.edu/downloads). 
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Statistical inference. The significance threshold was set to p<0.05, corrected for 
multiple comparisons within our a priori defined anatomical ROI, the hippocampus. 
For all analyses, we employed conservative analysis statistics by using family wise 
error rate (FWE), exerting strong control of type I error over multiple comparisons.  
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RESULTS 
Induction of MYT1L follows neural commitment, correlating with the expression of 
terminal differentiation genes 
To investigate the role of MYT1L in neural differentiation, we followed its expression 
in SPC04, a neural progenitor cell line that efficiently differentiates under defined 
culture conditions (Supplementary Methods). These cells express markers of 
differentiated neurons and produce neurite outgrowth starting 3 days after 
induction of differentiation (Desrivières et al, 2015). Microarray analyses indicated 
that proliferating, undifferentiated SPC04 cells express high levels of the stem cells 
markers ID 1 and ID3. The loss of proliferation correlated with drop in expression of 
these genes. Conversely, expression of NEUROG1 and NEUROG2 increased when 
that of ID1 and ID2 decreased, being maximal at the stage preceding induction of 
differentiation (Figure 1A). These patterns of expression contrasted sharply with that 
of MYT1L, whose expression was induced with differentiation, correlating with that 
of markers of terminal differentiation (Figure 1B). Functional annotation clustering 
confirmed that expression of MYT1L positively correlated with transcripts (r> 0.85; 
Supplementary Table 1) involved in neurite development and synaptic transmission.  
 
Knockdown of MYT1L enhances expression of ID1 and ID3 and inhibits neuronal 
differentiation  
We next studied the consequences of MYT1L loss of function on neuronal 
differentiation and gene expression. We infected SPC04 cells with lentiviruses 
encoding either a shRNA against MYT1L or a control shRNA and allowed them to 
differentiate for 7 or 14 days. As shown in Figure 2A, treatment with shMYT1L for 7 
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or 14 days, resulted in significant reduction of MYT1L mRNA levels (F(1,9) = 29.01, p 
= 0.002). Morphological examination of the infected cells indicated that while 
infection with control lentiviruses generated cells with apparent neuronal 
morphology with extended networks of neurites visible 7 days after induction of 
differentiation, infection with shMYT1L-expressing lentiviruses prevented these 
morphological changes, resulting in larger cell bodies and less elaborated neurite 
outgrowth (Figures 2B and 2C; see Supplementary Methods for quantification of 
neurite outgrowth). We then conducted microarray analyses to identify gene 
networks affected by MYT1L knockdown. These analyses indicated that most 
transcripts that were differentially expressed upon shMYT1L treatment were down-
regulated (Supplementary Table 2 and Figure 2D), indicating that MYT1L acts mainly 
as a transcriptional activator. Functional clustering analyses indicated that genes 
down-regulated by shMYT1L were enriched for genes involved in neurite outgrowth, 
axonal development, synaptic transmission and extracellular matrix composition 
(Figure 2E). Interestingly, the HLH ID1 and ID3 were among the few genes whose 
expression was induced upon MYT1L knockdown (Supplementary Table 2). These 
results suggested that MYT1L facilitates withdrawal from the cell cycle and 
commitment to neural differentiation by preventing expression of ID1 and ID3.   
 
Expression of MYT1L is inversely correlated with ID1 and ID3 levels in the human 
brain throughout the lifespan  
To investigate the relevance of these findings to human brain development, we 
analysed publicly available datasets of human post-mortem brain samples 
(Supplementary Methods), comparing the expression patterns of MYT1L, ID1 and ID3 
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in the human brain across the lifespan (Figure 3). MYT1L is expressed throughout the 
human brain. Its expression increases sharply during prenatal development to reach 
a maximum during mid and late stages of fetal development. Thereafter, expression 
of MYT1L drops, remaining moderate throughout childhood and adolescence and 
decreasing further in adult life. Such expression profile coincides with the expression 
of neuronal differentiation markers throughout the lifetime (data not shown but 
available upon request), overlapping with that of tissue- and region-specific bHLHs, 
such as NEUROD6. Conversely, expression of ID1 and ID3 follows reversed patterns, 
being highest when MYT1L expression is lowest (i.e., during embryonic development 
and childhood) and decreasing when MYT1L expression increased. These opposite 
expression patterns further support a functional antagonism between MYT1L and 
ID1/ID3. 
 
Mutations decreasing MYT1L expression in the human hippocampus associate with 
induction of ID1 and ID3 and repression of neural differentiation genes  
If, as suggested above, MYT1L represses expression of ID1 and ID3 in the human 
brain, mutations altering MYT1L functions should affect ID1 and ID3 levels such that 
their expression is induced when MYT1L is inhibited, or vice versa. To test this, we 
searched the UKBEC dataset (Trabzuni et al, 2012) for potential cis-acting eQTLs, that 
are SNPs within the MYT1L locus that correlate with altered MYT1L mRNA levels 
(Supplementary Methods).  We identified several such eQTLs, clustered around a 
conserved tissue-specific transcriptional enhancer upstream of MYT1L (Figure 4A; 
http://enhancer.lbl.gov/; (Visel et al, 2007)). The presence of minor alleles at these 
loci was associated with decreased expression of MYT1L specifically in the 
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hippocampus. This is illustrated in Supplementary Figure 1 for rs55800610, the most 
significant of these eQTLs. Individuals carrying the minor A-allele at this locus had 
significantly lower MYT1L mRNA levels in the hippocampus (P = 4.4 x 10-6). A similar, 
nominally significant decrease was also observed in the thalamus (P = 0.042) but not 
in eight other brain regions. As hypothesised, the reduction of MYT1L levels in the 
hippocampus of carriers of the rs55800610 A-allele was accompanied with 
significant increased levels of ID1 and ID3 (Figure 4B). 
This SNP also affected expression of a large number of genes in trans (N=850, 
FDR ≤ 0.05), most of which (> 90%), such as the proneural genes NEUROD6 and TCF4 
(Figure 4B and Supplementary Table 3), were down-regulated in carriers of the 
rs55800610 minor A-allele. The affected genes contributed largely to the regulation 
of synaptic transmission and long-term potentiation. Also noteworthy are significant 
enrichments for genes involved in intracellular signalling (calcium- and MAP kinase-
related signalling pathways), in cancer (glioma, non-small cell lung cancer) and in 
neurodegenerative diseases like amyotrophic lateral sclerosis and Alzheimer’s 
disease (Figures 4C and 4D).  
 
 
Mutation linked to decreased MYT1L expression associates with hippocampal 
volume and hippocampal activation during memory retrieval 
The results above suggested that MYT1L may play a role in development and 
function of the hippocampus. We investigated this further by analysing associations 
between MYT1L SNPs and structural and functional MRI in the human hippocampus. 
We first analysed possible associations between MYT1L and inter-individual 
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variations of hippocampal volume in IMAGEN, a cohort of N = 1,398 healthy 
adolescents, whose characteristics are listed in Supplementary Table 4. As 
rs55800610 was not directly genotyped in IMAGEN, we performed gene set-based 
analyses with SNPs genotyped in this sample to identify independent SNPs 
associating with hippocampal volume. For this, 95 SNPs contained within the MYT1L 
locus and its surrounding ± 10 kb region were tested for association by linear 
regression analyses taking LD between SNPs into account. Five SNPs in high LD were 
associated with right hippocampal volume below a p-value of 0.01. Only 1 of these, 
rs17338519, was independently significant based on an r-squared threshold of 0.5, 
remaining significant after 10,000 permutations (empirical p-value = 0.0098). For the 
left hippocampus, two SNPs in high LD (r2>0.5), including rs17338519, were 
associated with hippocampal volume below a p-value threshold of 0.01. However, 
this association did not remain significant after 10,000 permutations (empirical p-
value=0.3598). Linear regression analyses revealed significant association between 
genotypes at rs17338519 and right hippocampal volume. As shown in Figure 5A, the 
volume of the right hippocampus significantly decreased with the number of minor 
T-alleles at this locus (Beta = -75.96, p = 4.40 x 10-4, Figure 5A). Although no SNP 
passed the threshold of significance for analyses on the left hippocampus, we noted 
that the effects of rs17338519 on the right and left hippocampus were in the same 
direction (Beta = -55.55, p = 0.0079, for effects of rs17338519 on the left 
hippocampus). We also used the UKBEC dataset to test whether genotypes at 
rs17338519 were related to MYT1L expression levels in the human brain. Regression 
analyses indicated that the presence of the T-allele associated with decreased 
MYT1L mRNA levels in the hippocampus and the cortex (Beta = -0.22, p = 0.034; Beta 
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= -0.22, p = 0.0035; Figure 5B) 
To investigate a possible link between MYT1L and hippocampal function, we 
used an established reliable neuroimaging task (Erk et al, 2010), testing for the 
effects of rs17338519 on hippocampus activation during episodic memory recall in 
N=285 healthy individuals. We observed increased activation of the right 
hippocampus (x = 16, y = -6, z = -12; Z=3.65, p = 0.022 family wise error corrected for 
region of interest) during memory recall in carriers of the T-allele (Figure 5C). 
Genotype groups in this sample did not differ significantly for memory encoding or 
recognition. These data suggest that MYT1L maintains hippocampal structural 
integrity and its activation during learning and memory. 
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DISCUSSION 
We have shown for the first time that the MYT1L transcription factor regulates 
neurogenesis by repressing inhibitor of differentiation genes ID1 and ID3 and 
inducing proneural bHLH genes such as TCF4, NEUROD2 and NEUROD6. Loss of 
function experiments in vitro and the identification of deleterious mutations in the 
human brain indicated that this transcriptional regulator is necessary for the 
expression of genes implicated several aspects of neural development such as 
neurite outgrowth, axonal development and the regulation of synaptic transmission, 
as well as extracellular matrix composition. In line with a role for ID proteins in cell 
cycle and senescence (Ruzinova and Benezra, 2003), MYT1L-regulated genes were 
also enriched for genes involved in cancer and the neurodegenerative diseases 
amyotrophic lateral sclerosis and Alzheimer’s disease. Neuroimaging analyses 
indicated that expression of MYT1L in the hippocampus associates with 
hippocampus volume and activation during episodic memory recall. Thus, we 
propose that MYT1L controls neural development and influences cognitive capacity 
by displacing the balance of bHLH and ID factors such that bHLH predominate.  
 
 The links that we identified between MYT1L and ID gene expression are 
interesting. Id proteins control proliferation and differentiation of a variety of tissue-
specific stem cells in response to signalling pathways triggered by their extracellular 
microenvironment (Chaudhary et al, 2001; Jankiewicz et al, 2006; Niola et al, 2012; 
Ying et al, 2003; Yokota et al, 1999). In this context, one notable finding is the link 
that we established between MYT1L and extracellular matrix gene expression. 
Interestingly, RAP1GAP, a gene downregulated by loss of function of MYT1L, both in 
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SPC04 cells and in the hippocampus (Figure 4E and Supplementary Tables 2 & 3), is 
known as a direct target of the bHLH–Id transcriptional pathway that encodes a key 
regulator of cell adhesion, as determined by investigations in the developing mouse 
brain. Id-mediated repression of Rap1GAP has been found to enhance adhesion of 
neural stem cells to their extracellular microenvironment, thereby synchronizing 
neural stem cell functions to residency in the specialized stem cell niche (Niola et al, 
2012). Therefore, MYT1L-mediated negative control of ID expression may activate a 
transcriptional program to synchronize the committed differentiation of neural stem 
cell progenitors and their detachment from the stem cell niche. Consistent with this 
role in regulating stem cell anchorage to the niche and neural differentiation, 
ID1/RAP1GAP has a central role in tumour formation, particularly in the formation of 
highly aggressive glioblastomas (Niola et al, 2013; Soroceanu et al, 2013). Our results 
also implicate MYT1L in glioma formation, through a process that besides RAP1GAP, 
may require MAP kinases and calcium-dependent signalling mechanisms (Ren et al, 
2007). Indeed, the MYT1L gene was found to be deleted in about 5% of glioblastoma 
multiforme samples and the protein absent or down-regulated in more than 80% of 
these samples (Hu et al, 2013), leading to the suggestion that gliomagenesis requires 
neutralization of terminal differentiation. 
 
Importance of the MYT1L-ID-HLH network for normal brain development and 
function is reflected by the severe developmental delays and complex phenotypes 
associated with disruptions in some of its core components. While MYT1L mutations 
have been associated with intellectual disability with early onset obesity (Doco-
Fenzy et al, 2014; Stevens et al, 2011), autism (Meyer et al, 2012; Rio et al, 2013) 
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and schizophrenia (Lee et al, 2012; Vrijenhoek et al, 2008), TCF4 mutations cause 
Fuchs’corneal endothelial dystrophy, Pitt–Hopkins syndrome, a disorder that is part 
of the clinical spectrum of Rett-like syndromes characterized by intellectual disability 
and developmental delay (Whalen et al, 2012), and have been described in patients 
with schizophrenia, autism and other neurodevelopmental disorders (Forrest et al, 
2014). Strinkingly, expression of ID genes is also linked to Rett syndrome (Wang et al, 
2015). These genes are repressed by MeCP2, a gene required for maturation of 
neurons and whose defect causes Rett syndrome, mental retardation, 
encephalopathy and autism susceptibility (Gao et al, 2015; Peddada et al, 2006). 
Such results indicate that differential regulation of the ID-HLH pathway by MYT1L 
may underlie the phenotypic overlap of several neurodevelopmental disorders. 
The identification of genetic variants affecting MYT1L expression in the 
hippocampus had guided our MRI studies on the hippocampus. The location of the 
rs55800610 variant within a highly conserved tissue-specific enhancer that directs 
spatially restricted gene expression in the developing brain might underlie the 
restricted effect of this SNP in the hippocampus, as rs17338519 that is not located in 
such regulatory region has broader effects in the brain. Finding such functions for 
MYT1L in the hippocampus is in agreement with this region being one of the few in 
the mammalian brain that retains its ability to produce functional neurons 
throughout life. Besides its major role in postnatal neurogenesis (Schwarz et al, 
2012) the hippocampus is crucial for episodic memory (Bliss and Collingridge, 1993)  
and changes in hippocampal volumes are hallmarks of several common neurological 
and psychiatric disorders including mental retardation (Nadel, 2003). Yet, the 
hippocampus is not the only key brain area for memory and more generally, 
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cognitive ability. Structural and functional neuroimaging have revealed a network of 
cortical brain areas involved in general cognitive functions (Deary et al, 2010). Our 
findings that the minor allele at rs17338519, that affects hippocampal activation 
during memory recall, is linked with decreased MYT1L expression in both 
hippocampus and cortex are in agreement with this. 
 
It is remarkable that the learning and memory deficits of subjects with 
intellectual disability are associated with decreased size of the hippocampus and 
impairments of the prefrontal cortex and hippocampal system. These deficits 
become considerably more noticeable during late childhood and adolescence (Nadel, 
2003),  possibly as genetic factors underlying inter-individual variability in these 
brain systems become effective at this stage of development (Haworth et al, 2010). 
Our data suggest that MYT1L is one of these factors underlying inter-individuals 
differences in hippocampal volume. The increased hippocampal activation observed 
in our fMRI study also suggests that decreased MYT1L levels may lessen neuronal 
efficiency during cognitive task performance. However, we acknowledge that the use 
of two distinct cohorts of different ages for our MRI analyses has limitations. Future 
longitudinal studies of cohorts with structural MRI and suitable fMRI assessments 
are required to determine if genetic alterations in MYT1L predispose to changes in 
brain structure and function across the lifetime. Nonetheless, the discoveries 
described here provide aetiologically relevant mechanistic explanations for a role of 
MYT1L in neural development.  
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FIGURE LEGENDS 
 
Figure 1: Changes in gene expression patterns during differentiation of the human 
neural stem cell line SPC04. Changes in HLH (ID1 and ID3) and bHLH (NEUROG1 and 
NEUROG2) mRNA levels (A), and induction of a subset of terminal differentiation 
genes co-expressed with MYT1L (B) were accessed by microarray analyses. Results 
show variations in expression in various stages of differentiation (pre-differentiation, 
and 3 or 7 days after induction of differentiation), relative to that of undifferentiated 
cells and represent mean ± SEM of n=3 independent experiments.   
 
Figure 2: Effects of MYT1L knockdown on neural differentiation and global gene 
expression in SP04 cells. Cells were transduced with lentiviral vectors encoding 
shMYT1L or a non-silencing shRNA control and induced to differentiate for 7 or 14 
days. A) Efficiency of MYT1L knockdown accessed by PCR 7 and 14 days after 
induction of differentiation. Effects of treatment with shMYT1L on MYT1L and mRNA 
levels, split according to the length of differentiation. Results represent mean ± SEM 
of n=3 independent experiments; **, p < 0.01. B) Effects of shMYT1L on morphology 
of SPC04 cells, 7 days after induction of differentiation. Changes in morphology are 
evident when comparing phase contrast pictures of cells transduced with control, 
non-silencing lentiviruses with that of cells transduced with shMYT1L-encoding 
lentiviruses: control cells showed enhanced neuronal features such as increased 
neurite elongation and retracted cell bodies. In contrast, shMYT1L prevented these 
morphological changes, resulting in a flat, more adherent morphology. The 
fluorescence pictures reveal the high efficiency of transduction by the lentiviruses 
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that expressed the enhanced green fluorescent protein as marker. Scale bar = 
100μm.  C) Quantification of the morphological changes described in B) were 
obtained using the neurite outgrowth plugin in MetaMorph; total neurite length and 
average length of neurite per cell and cell soma area were recorded in a total of 473 
cells (number of cells per group: control MYT1L, n = 298; shMYT1L, n= 175). 
Unpaired t-tests were used to compare means in each group: ****, p < 0.0001. D) 
Microarray mRNA profiling analysis reveals target genes differentially affected by 
MYT1L. Probe sets differentially expressed following shMYT1L treatment were 
clustered together based on euclidean distance, and their expression levels (each 
line represents a single probe set) are displayed as fold change compared to control 
treatment. E) Functional clustering of differently expressed genes showing 
enrichment for genes involved in neuronal maturation and the extracellular matrix 
composition. 
 
Figure 3: Analyses of gene expression in the human brain across the lifetime 
reveals patterns of MYT1L mRNA expression that correlates highly with that of 
NEUROD6, notably in the neocortex, the hippocampus and the amygdala. 
Conversely, MYT1L expression correlates inversely with that of ID1 and ID3 
throughout the life span. 
 
Figure 4: Effects of a MYT1L-associated eQTL on gene expression in the 
hippocampus. A) Genomic view of the MYT1L locus, indicating SNPs acting in cis 
to influence MYT1L expression (MYT1L eQTLs, red bars). These SNPs are all in 
high linkage disequilibrium (r2 > 0.8), surrounding a conserved distant-acting and 
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tissue-specific transcriptional enhancer (i.e., human element hs1385, labeled as 
element_1385) from the VISTA Enhancer database, (Pennacchio et al, 2006)). 
Genomic coordinates are based on the hg19 genome assembly. B) The minor 
alleles at these eQTLs decrease mRNA levels of MYT1L (cis-effects) in the 
hippocampus, as illustrated for the rs55800610 gene variant. The minor A-allele 
at this SNP also associates with reduced NEUROD6 and TCF4 mRNA levels and 
increased mRNA levels of ID1 and ID3 in the hippocampus (trans-effects). 
Because of the low minor allele frequency (MAF = 0.07), heterozygotes and 
individuals homozygotes for the minor allele were grouped for analyses. 
Genotypes count: A-carriers (AA + AT), n= 20; TT, n= 114. C-D) Gene set 
enrichment analyses of all genes down-regulated in individuals carriers of the 
rs55800610 A-allele indicating their clustering into specific biological functions 
(C) and belonging to a known biological pathway (D). The dashed vertical line 
represents the significance threshold (Padj  0.05). E) Genes whose expression is 
affected by MYT1L decrease both in SPC04 cells and in the human hippocampus, 
and the measured effect sizes (negative = down-regulation, positive = up-
regulation). 
 
Figure 5: Associations between MYT1L expression and hippocampus volume and 
hippocampus activation during episodic memory recall. A) Association of rs17338519 
with hippocampal volume in a sample of N = 1,398 adolescents. Linear regression 
analyses indicated that the number of minor T-alleles associated with lower volume 
of the right hippocampus (P = 4.40 x 10-4). B) Expression of MYT1L stratified by 
genotypes at rs17338519, in the hippocampus and cerebral cortex of 134 post-
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mortem human brains. For the cortex, expressions of MYT1L in the occipital, 
temporal and frontal cortices were averaged.  Regression analyses indicated that the 
presence of the T-allele at rs17338519 associated with decreased MYT1L mRNA 
levels in the hippocampus (P = 0.034) and the cortex (P = 0.0035). Genotypes count: 
GG = 110; T-carriers = 24. C) Association of rs17338519 with hippocampal activation 
during an fMRI task of episodic memory recall in 285 healthy adults. The left panel 
shows the ROI-derived brain activation map within the hippocampus, with increased 
activation of the right hippocampus (x = 16, y = -6, z = -12) during episodic memory 
recall in carriers of the T-allele (N=285; p=0.02 family wise error (FWE) corrected for 
multiple testing across region of interest). The right panel shows a quantification of 
rs17338519 genotypes effects on the activation of the right hippocampus. Each dot 
represents size of effect in one subject.  
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